nab-Paclitaxel (Abraxane®): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors

被引：0
|
作者：
J Iglesias
机构：
[1] Abraxis Bioscience,
来源：
Breast Cancer Research | / 11卷
关键词：
Paclitaxel; Docetaxel; Metastatic Breast Cancer; Taxanes; Polysorbate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)
    Houghton, Peter J.
    Kurmasheva, Raushan T.
    Kolb, E. Anders
    Gorlick, Richard
    Maris, John M.
    Wu, Jianrong
    Tong, Zeen
    Arnold, Michael A.
    Chatterjee, Moumita
    Williams, Terence M.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (07) : 1214 - 1221
  • [22] DIFFERENT PATTERNS OF TREATMENT WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR TARGETED CHEMOTHERAPY IN METASTATIC BREAST CANCER: A MULTICENTER ITALIAN EXPERIENCE ON 125 WOMEN
    Palumbo, Raffaella
    Cazzaniga, Marina
    Piazza, Elena
    Tondini, Carlo
    Ferzi, Antonella
    Grasso, Donatella
    Danova, Marco
    Tarenzi, Emiliana
    Sottotetti, Federico
    Villa, Federica
    Gambaro, Anna
    Caremoli, Elena Rota
    Collova, Elena
    Cavalli, Carla
    Bernardo, Antonio
    BREAST, 2013, 22 : S41 - S41
  • [23] Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
    Cortes, Javier
    Saura, Cristina
    EJC SUPPLEMENTS, 2010, 8 (01): : 1 - 10
  • [24] Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
    Zhang, Dong-sheng
    Wang, De-shen
    Wang, Zhi-qiang
    Wang, Feng-hua
    Luo, Hui-yan
    Qiu, Miao-zhen
    Wang, Feng
    Li, Yu-hong
    Xu, Rui-hua
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 1065 - 1072
  • [25] Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
    Dong-sheng Zhang
    De-shen Wang
    Zhi-qiang Wang
    Feng-hua Wang
    Hui-yan Luo
    Miao-zhen Qiu
    Feng Wang
    Yu-hong Li
    Rui-hua Xu
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1065 - 1072
  • [26] Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
    Carrato, Alfredo
    Garcia, Pilar
    Lopez, Rafael
    Macarulla, Teresa
    Rivera, Fernando
    Sastre, Javier
    Gostkorzewicz, Joana
    Benedit, Patricia
    Perez-Alcantara, Ferran
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 579 - 589
  • [27] Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma
    Altundag, Kadri
    Dede, Didem S.
    Purnak, Tugrul
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (08) : 958 - 958
  • [28] In vivo radiation enhancement by ABI-007, a nanoparticle albumin-bound (nab) paclitaxel
    Wiedenmann, N.
    Valdecanas, D.
    Farrar, D.
    Milas, L.
    Mason, K.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 13 - 14
  • [29] A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
    Paul K. Paik
    Leonard P. James
    Gregory J. Riely
    Christopher G. Azzoli
    Vincent A. Miller
    Kenneth K. Ng
    Camelia S. Sima
    Robert T. Heelan
    Mark G. Kris
    Erin Moore
    Naiyer A. Rizvi
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1331 - 1337
  • [30] Antitumor activity, and antiangiogenic activity of nanoparticle albumin-bound nab-rapamycin in combination with nab-paclitaxel.
    Desai, N.
    Ran, S.
    Volk, L.
    Stutzman, A.
    D 'Cruz, O.
    Trieu, V
    CANCER RESEARCH, 2009, 69 (02) : 239S - 239S
12345